Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1

Scand J Infect Dis. 2004;36(6-7):527-8. doi: 10.1080/00365540310016169.

Abstract

Tenofovir disopril fumarate, a new nucleotide analogue against human immunodeficiency virus-1 (HIV-1), can induce hypophosphataemia, the mechanism of which is unclear. Moreover, a renal tubulopathy can occur in long-term treated patients, as observed in 2 HIV-1-infected patients after 12 months of tenofovir therapy, with polyuria-polydipsia, proteinuria, glycosuria and amino-aciduria, which resolved after discontinuation of tenofovir. The risk of renal tubulopathy symptoms in patients on long-term tenofovir therapy should be noted.

Publication types

  • Case Reports

MeSH terms

  • Adenine / administration & dosage
  • Adenine / adverse effects*
  • Adenine / analogs & derivatives*
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects*
  • Drug Therapy, Combination
  • Fanconi Syndrome / etiology
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects
  • Humans
  • Hypophosphatemia / etiology*
  • Kidney Tubules / pathology*
  • Organophosphonates*
  • Organophosphorus Compounds / administration & dosage
  • Organophosphorus Compounds / adverse effects*
  • Polyuria / etiology
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / adverse effects*
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Organophosphorus Compounds
  • Reverse Transcriptase Inhibitors
  • Tenofovir
  • Adenine